PD-1/PD-L1 signaling pathway and its application in tumor
10.13220/j.cnki.jipr.2015.02.003
- VernacularTitle:PD-1/PD-L1信号通路及其在肿瘤中的应用
- Author:
Shi WANG
;
Longlong LUO
;
Ming LV
;
Yuanfang MA
- Publication Type:Journal Article
- Keywords:
programmed death-1;
programmed death-L1;
signaling pathway;
monoclonal antibody
- From:
Journal of International Pharmaceutical Research
2015;(2):143-147
- CountryChina
- Language:Chinese
-
Abstract:
PD-1/PD-L1 signaling pathway as a T cell immune response co-stimulatory signaling pathway plays an important role in adaptive immunity. PD-1 is a major co-receptor expressing on T cells, binding with its ligands(PD-L1 and PD-L2), PD-1 can inhibit T cell activation and protect the body against the attacks from its own immune system. In addition to adjusting and maintaining autoimmune tolerance, in tumor cells PD-L1 expression is up-regulated, while in the virus-infected T cells PD-L1 expression is also upregulated. PD-1 / PD-L1 are involved in the tumor and infectious pathogen immune evasion, thus blocking the PD-1 / PD-L1 signaling pathway has become a hot research of cancer and chronic diseases. Currently, there are several anti-PD-1 or PD-L1 monoclonal antibodies approved by the FDA to enter clinical studies, which have shown significant anti-cancer effect.
